Systematic evidence on the prevalence and clinical outcome of transthyretin amyloidosis (ATTR) is missing. We explored: (i) the prevalence of cardiac amyloidosis in various patient subgroups, (ii) survival estimates for ATTR subtypes, and (iii) the effects of novel therapeutics on the natural course of disease.

中文翻译：

---

转甲状腺素蛋白淀粉样变性的患病率和临床结果：系统评价和荟萃分析

缺少关于转甲状腺素蛋白淀粉样变性 (ATTR) 患病率和临床结果的系统证据。我们探索了：(i) 心脏淀粉样变性在不同患者亚组中的患病率，(ii) ATTR 亚型的生存估计，以及 (iii) 新疗法对疾病自然病程的影响。